Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 10/20 | 0.38 |
| ▸ | CNR1 | P21554 | 8/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.33 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568783 | 0.93 | PTGS2 (0.40) | PTGS2CNR2CNR1DHFRSPHK2 | |
| SCHEMBL6567276 | 0.88 | PTGS2 (0.38) | PTGS2CNR2CNR1ALOX5 | |
| SCHEMBL6565887 | 0.87 | CNR2 (0.37) | PTGS2CNR2CNR1ALOX5 | |
| SCHEMBL7796629 | 0.85 | THRA (0.46) | PTGS2CNR2CNR1TNFRSF1A | |
| SCHEMBL6567472 | 0.84 | DHFR (0.38) | PTGS2DHFRTNFRSF1A | |
| SCHEMBL7944896 | 0.84 | CNR2 (0.39) | CNR2CNR1ALOX5 | |
| SCHEMBL6567279 | 0.84 | DHFR (0.43) | PTGS2DHFRTNFRSF1A | |
| SCHEMBL6565809 | 0.83 | DHFR (0.37) | PTGS2DHFRTNFRSF1A | |
| SCHEMBL6568772 | 0.82 | GAA (0.45) | PTGS2 | |
| SCHEMBL7786486 | 0.82 | THRB (0.45) | CNR2CNR1TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1484334-A2 | Process for producing phosphite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040225145-A1 | Process for producing phosphite | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-11-11 | — | — | US | disclosed |
| US-6242514-B1 | CYCLIC PHOSPHATE OR PHOSPHONATE; HEAT AND OXIDATION STABILIZER ESPECIALLY FOR OLEFIN POLYMERS AND ENGINEERING THERMOPLASTICS | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-5914361-A | IMPART HEAT STABILITY TO ORGANIC MATERIALS, INCLUDING POLYOLEFINS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-06-22 | — | — | US | disclosed |
| US-5889095-A | OXYGEN AND HEAT RESISTANCE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| EP-0823435-A2 | Phosphites, process for producing the same and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225145-A1 | Process for producing phosphite | PHOSPHO1, PLCG1, PLCG2 | PTGS2 2133/4885CNR2 1787/4885CNR1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.